JP2012531219A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012531219A5 JP2012531219A5 JP2012518929A JP2012518929A JP2012531219A5 JP 2012531219 A5 JP2012531219 A5 JP 2012531219A5 JP 2012518929 A JP2012518929 A JP 2012518929A JP 2012518929 A JP2012518929 A JP 2012518929A JP 2012531219 A5 JP2012531219 A5 JP 2012531219A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- domain
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 38
- 241000725303 Human immunodeficiency virus Species 0.000 claims 12
- 235000001014 amino acid Nutrition 0.000 claims 12
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 10
- 238000009739 binding Methods 0.000 claims 9
- 102000002110 C2 domains Human genes 0.000 claims 8
- 108050009459 C2 domains Proteins 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 7
- 208000030507 AIDS Diseases 0.000 claims 6
- 230000002163 immunogen Effects 0.000 claims 5
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 108010016626 Dipeptides Proteins 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 230000010933 acylation Effects 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 108010087924 alanylproline Proteins 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 238000011225 antiretroviral therapy Methods 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 235000013477 citrulline Nutrition 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000568 immunological adjuvant Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000011191 terminal modification Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09164565.5 | 2009-07-03 | ||
| EP09164565 | 2009-07-03 | ||
| US22343609P | 2009-07-07 | 2009-07-07 | |
| US61/223,436 | 2009-07-07 | ||
| PCT/EP2010/059513 WO2011000962A2 (en) | 2009-07-03 | 2010-07-03 | Novel therapeutic and diagnostic means |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012531219A JP2012531219A (ja) | 2012-12-10 |
| JP2012531219A5 true JP2012531219A5 (https=) | 2013-08-15 |
| JP5946766B2 JP5946766B2 (ja) | 2016-07-06 |
Family
ID=42752402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012518929A Expired - Fee Related JP5946766B2 (ja) | 2009-07-03 | 2010-07-03 | Ｈｉｖワクチン組成物における使用又は診断手段としての使用のためのｈｉｖ関連ペプチドの組合せ又は融合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9200065B2 (https=) |
| EP (1) | EP2448593B1 (https=) |
| JP (1) | JP5946766B2 (https=) |
| CN (1) | CN102711791A (https=) |
| BR (1) | BR112012000032A2 (https=) |
| CA (1) | CA2767063A1 (https=) |
| EA (1) | EA022788B1 (https=) |
| NZ (1) | NZ597458A (https=) |
| WO (1) | WO2011000962A2 (https=) |
| ZA (1) | ZA201200370B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2767063A1 (en) | 2009-07-03 | 2011-01-06 | Bionor Immuno As | Novel therapeutic and diagnostic means |
| US9493514B2 (en) * | 2011-01-06 | 2016-11-15 | Bionor Immuno As | Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes |
| FR2987836A1 (fr) * | 2012-03-09 | 2013-09-13 | Biomerieux Sa | Peptides d'interference et procede de detection de microorganismes |
| IN2014KN02774A (https=) * | 2012-06-06 | 2015-05-08 | Bionor Immuno As | |
| JP6310909B2 (ja) * | 2012-06-06 | 2018-04-11 | ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ | 免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド |
| WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
| AU2015208033B2 (en) | 2014-01-27 | 2019-02-07 | Bionor Immuno As | Method for the vaccination against HIV |
| PT3166607T (pt) | 2014-07-11 | 2022-12-07 | Gilead Sciences Inc | Moduladores de receptores de tipo toll para o tratamento do vih |
| WO2016168758A1 (en) * | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| CN106282214A (zh) * | 2016-08-03 | 2017-01-04 | 康众（北京）生物科技有限公司 | 一种快速获得纳米抗体的方法及其应用 |
| RU2642258C1 (ru) * | 2016-12-27 | 2018-01-24 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Рекомбинантный химерный полипептид-иммуноген nTBI, обладающий способностью индуцировать антитела, нейтрализующие вирус иммунодефицита человека 1 типа, и предназначенный для использования в качестве компонента вакцины против ВИЧ-1 |
| CN108593601A (zh) * | 2018-04-11 | 2018-09-28 | 珠海国际旅行卫生保健中心 | 一种快速检测HIV-1的SPRi生物芯片制备方法及其应用 |
| CN113143974B (zh) * | 2021-03-03 | 2023-06-06 | 武汉科技大学 | 一种hiv感染致神经损伤动物模型的建立方法及其用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US4596792A (en) | 1981-09-04 | 1986-06-24 | The Regents Of The University Of California | Safe vaccine for hepatitis containing polymerized serum albumin |
| JPS5938877A (ja) | 1982-08-30 | 1984-03-02 | Musashi Eng Kk | 紙葉判別方法 |
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
| US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5298419A (en) * | 1988-03-31 | 1994-03-29 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Human hybridomas and monoclonal antibodies which bind both gp41 and gp120 envelope proteins of human immunodeficiency virus |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
| HUT62316A (en) | 1990-09-25 | 1993-04-28 | Hiver Ltd | Process for producing aids vaccine and for diagnosing aids |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5697151A (en) | 1995-08-07 | 1997-12-16 | General Electric Company | Method for repairing partitions of a turbine diaphragm |
| EP1005374B1 (en) | 1997-01-22 | 2007-04-18 | Zycos Inc. | Microparticles for delivery of nucleic acid |
| CN1195702A (zh) | 1997-04-08 | 1998-10-14 | 军事医学科学院基础医学研究所 | Hiv－1多表位重组膜抗原及其表达 |
| EP0981548A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF |
| IL141868A0 (en) | 1998-10-05 | 2002-03-10 | M & E Biotech As | Novel methods for therapeutic vaccination |
| US6911527B1 (en) * | 1999-01-11 | 2005-06-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | HIV related peptides |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2005040219A1 (en) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| EP2205256A4 (en) * | 2007-09-26 | 2012-10-24 | Dana Farber Cancer Inst Inc | REAGENTS TO TRIGGER IMMUNE REACTION |
| CN101969975B (zh) * | 2008-01-31 | 2013-06-05 | 生控基因疫苗股份有限公司 | 作为疫苗的hiv嵌合融合蛋白 |
| CA2767063A1 (en) | 2009-07-03 | 2011-01-06 | Bionor Immuno As | Novel therapeutic and diagnostic means |
-
2010
- 2010-07-03 CA CA2767063A patent/CA2767063A1/en not_active Abandoned
- 2010-07-03 NZ NZ597458A patent/NZ597458A/en not_active IP Right Cessation
- 2010-07-03 US US13/382,137 patent/US9200065B2/en not_active Expired - Fee Related
- 2010-07-03 BR BR112012000032A patent/BR112012000032A2/pt not_active IP Right Cessation
- 2010-07-03 EP EP10736997.7A patent/EP2448593B1/en active Active
- 2010-07-03 CN CN2010800392328A patent/CN102711791A/zh active Pending
- 2010-07-03 WO PCT/EP2010/059513 patent/WO2011000962A2/en not_active Ceased
- 2010-07-03 EA EA201270124A patent/EA022788B1/ru not_active IP Right Cessation
- 2010-07-03 JP JP2012518929A patent/JP5946766B2/ja not_active Expired - Fee Related
-
2012
- 2012-01-17 ZA ZA2012/00370A patent/ZA201200370B/en unknown
-
2015
- 2015-11-25 US US14/952,292 patent/US10251949B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012531219A5 (https=) | ||
| CN103483421B (zh) | 用于治疗hbv感染及相关疾病的多肽及抗体 | |
| JP6735269B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| JP6643981B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| GB2598494A (en) | A subunit vaccine for treatment or prevention of a respiratory tract infection | |
| US20040213801A1 (en) | Methods of eliciting broadly neutralizing antibodies targeting HIV-1 gp41 | |
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| JP2013543497A5 (https=) | ||
| WO2011008863A4 (en) | Stereoisomer peptides and their polymer conjugates for hiv disease | |
| JP2013501030A (ja) | 新規抗病原性ペプチド | |
| WO2000027880A2 (en) | Rantes-derived peptides with anti-hiv activity | |
| WO2011110049A1 (zh) | 抗hiv的融合多肽及其用途 | |
| AU2017350304B2 (en) | Influenza virus neutralizing compounds | |
| US10550171B2 (en) | Immunomodulatory peptides and methods of use thereof | |
| JP6921002B2 (ja) | ペプチド模倣化合物を中和するインフルエンザウイルス | |
| RU2014107838A (ru) | ГИПОАЛЛЕРГИЧЕСКИЕ ВАРИАНТЫ Mal d 1, ГЛАВНОГО АЛЛЕРГЕНА Malus domectica | |
| ES2202321T3 (es) | Peptidos para uso en la vacunacion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana. | |
| WO2021260176A1 (en) | Synthetic epitopes of betacoronaviruses | |
| JP7167088B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| JP2004509846A (ja) | 肝炎ｃ型ウイルスコンジュゲート | |
| TW202306966A (zh) | 人類α突觸核蛋白之抗原決定位肽及包含該肽之醫藥組合物 | |
| WO2025073720A1 (en) | Recombinant hepatitis c virus glycoproteins, composition and application(s) thereof | |
| US20030224011A1 (en) | Hepatitis c virus conjugates | |
| JPWO2022265091A5 (https=) | ||
| JP2023508777A (ja) | インターロイキン－６に対して指向される免疫応答を誘導するための免疫原性複合体 |